How has been the historical performance of Johnson Pharma?

Answer:The historical performance of Johnson Pharma shows significant fluctuations in revenue and profitability over the years, with a notable decline in recent periods. Breakdown: Johnson Pharma's net sales peaked at 3.26 Cr in March 2022 but have since dropped to 0.00 Cr in March 2025. Total operating income followed a similar trend, decreasing from 3.26 Cr in March 2022 to 0.00 Cr in March 2025. The company experienced an operating profit of 0.13 Cr in March 2022, but this turned negative, resulting in an operating loss of 0.41 Cr by March 2025. Profit before tax also saw a decline, moving from a profit of 0.13 Cr in March 2022 to a loss of 0.58 Cr in March 2025. The profit after tax mirrored this trend, with losses increasing from 0.10 Cr in March 2022 to 0.58 Cr in March 2025. Total assets decreased from 59.98 Cr in March 2022 to 57.93 Cr in March 2025, while total liabilities also fell from 59.98 Cr to 57.93 Cr in the same period. Cash flow from operating activities turned negative, with a cash outflow of 1.00 Cr in March 2025, contrasting with a positive cash flow of 4.00 Cr in March 2022. Overall, the financial data indicates a downward trajectory in both operational performance and financial stability for Johnson Pharma.